A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
Public ClinicalTrials.gov record NCT00402077. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Parallel-Group, Multicenter Study to Examine the Safety, Tolerability, and Body Weight Effect of Subcutaneous Pramlintide Alone and in Combination With the Oral Antiobesity Agents Sibutramine or Phentermine in Overweight and Obese Subjects
Study identification
- NCT ID
- NCT00402077
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 258 participants
Conditions and interventions
Conditions
Interventions
- pramlintide acetate Drug
- sibutramine Drug
- phentermine Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2006
- Primary completion
- Jul 31, 2007
- Completion
- Jul 31, 2007
- Last update posted
- Mar 5, 2015
2006 – 2007
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | — | — |
| Research Site | Phoenix | Arizona | — | — |
| Research Site | Chula Vista | California | — | — |
| Research Site | La Jolla | California | — | — |
| Research Site | Los Angeles | California | — | — |
| Research Site | Walnut Creek | California | — | — |
| Research Site | Miami | Florida | — | — |
| Research Site | Pembroke Pines | Florida | — | — |
| Research Site | Louisville | Kentucky | — | — |
| Research Site | New York | New York | — | — |
| Research Site | Raleigh | North Carolina | — | — |
| Research Site | Statesville | North Carolina | — | — |
| Research Site | Eugene | Oregon | — | — |
| Research Site | Philadelphia | Pennsylvania | — | — |
| Research Site | Austin | Texas | — | — |
| Research Site | San Antonio | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00402077, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2015 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00402077 live on ClinicalTrials.gov.